Kidney AI suite
Chronic Kidney Disease (CKD) affects around 850 million people worldwide and is predicted to become the fifth global cause of death by 2040. Histopathologic assessment of renal biopsies remains the gold standard for diagnosing various kidney diseases, while primary histologic indicators are also used for prognosis of disease progression.
Aiosyn is developing AI-powered algorithms that provide objective quantification of kidney lesion scores, saving time and improving the reproducibility of results1. Explore your opportunities and partner with us to improve your research workflow.
1. Aiosyn’s Kidney AI suite is for Research Use Only and should not be used for diagnostic procedures.
-
Biopharma services
-
Discovery and Translational research
-
Clinical development
-
Aiosyn develops AI-powered algorithms to facilitate precision diagnostics strategies which may improve future therapy development and optimization. Our team uses artificial intelligence (AI) technology, high-quality pathology images, and data science expertise in the field of renal disease to develop a digital pathology and AI strategy for customers’ preclinical and biomarker development projects.
Our team has a proven track record in developing AI-powered algorithms. With our pathologist’s network and high-quality data, we develop and validate AI models for quantitative, accurate, and scalable predictive analytics to complement drug development studies.
Aiosyn’s cloud-based diagnostics platform ensures integration and scalable deployment of algorithms for clinical development studies.
-
Aiosyn’s kidney AI suite can advance discovery and translational research in the field of renal diseases. By harnessing the power of AI technology, we provide a platform that assists groundbreaking exploration and analysis in this field.
Partner with the Aiosyn team to discover new morphologic features, biomarkers and spatial patterns using AI solutions. These data-driven insights will support your custom analytical and modeling strategies and combine quantitative assessment of animal models with downstream experiments.
-
By leveraging AI algorithms and advanced image analysis techniques, Aiosyn facilitates the identification and characterization of specific histopathological features and patterns that hold valuable insights into disease progression and treatment response.
The detection and analysis of these histopathological biomarkers using AI technology will support the identification of patient (sub)groups to enable more informed decision-making and provide an objective measurement to improve the efficiency of clinical trials. This may ultimately lead to more targeted therapies for kidney disease.
How can we assist your team?
- AI-powered algorithms to quantify kidney lesion scores such as glomerular damage and interstitial fibrosis.
- Objective quantification to improve the reproducibility of results.
- Improved objectivity of pathologist’s assessments in multi-center clinical studies.
- Customized projects for known and new biomarkers
Segmentation of main tissue classes
Our AI can accurately segment relevant kidney structures, among which: (sclerotic) glomeruli, proximal/distal/atrophic tubuli, arteries & capsule. Leveraging this data, we can provide a wide variety of quantitative and spatial measurements, such as the number of glomeruli in a biopsy or the tissue area consisting of interstitium.
AI-Powered quantification of fibrosis
Renal fibrosis is a key biomarker for CKD progression and for prognosis of kidney transplantation. Current scoring systems are based on crude semi-quantitative assessments, limited to the capability of the human eye. AI-based fibrosis quantification yields an objective and precise measurement that can aid pathologists and biopharma services with their assessments.
Localization and counting of glomeruli
The assessment of glomeruli is a quality assessment of every renal biopsy. Our AI-powered algorithms provide a quantitative glomerular count, boosting diagnostic efficiency and improving the reproducibility for Chronic Kidney Disease (CKD) treatment planning.
Our AI solutions for the analysis of renal samples have been co-developed with kidney pathology experts, using high-quality images, and data science expertise in the field of renal disease.
At Aiosyn, we focus on facilitating accessibility and integration of our deep learning technology into existing workflows. Book a demo to discover how our software works on your images and how it will support your research lab with improved efficiency and reproducibility of results.